Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?

Nature Clinical Practice Oncology

Volumn 3, Issue 1, 2006, Pages 16-17

  Orlowski, Robert Z ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bortezomib; Dexamethasone; Multiple myeloma; Proteasome inhibitor

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; VELCALDE;

ANOREXIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HUMAN; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RISK REDUCTION; SHORT SURVEY; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 30944467973     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0382     Document Type: Short Survey

References (5)

1. Hideshima T et al. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076
2. Orlowski RZ et al. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20: 4420-4427
3. Richardson PG et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617
4. Jagannath S et al. (2005) Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials [abstract #6501]. J Clin Oncol 24 (Suppl): 560s
5. Orlowski RZ et al. (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105: 3058-3065